The Business Journals

S.F. biopharma startup scores $38M for targeting enzymes that may slow or halt Parkinson’s

In non-coronavirus news, South San Francisco biopharma company Nitrome Biosciences secured $38 million in a Series A financing round to develop drugs for slowing or stopping the progression of ...
Business Wire

Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases

SAN FRANCISCO--(BUSINESS WIRE)--Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around a newly identified class of enzymes to target Parkinson’s disease ...
Yahoo Finance

Nitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson

SAN FRANCISCO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around its newly discovered class of enzymes to target ...
Yahoo Finance

Nitrome Biosciences Appoints Industry Veteran Perry Karsen as Executive Chairman of the Board of Directors

SAN FRANCISCO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around its newly discovered class of enzymes to target ...
FierceBiotech

AbbVie-backed Nitrome adds BMS as investor in $45M series A, snags Nurix CBO as CEO and rebrands to Nitrase

Don't be confused. Nitrome Biosciences isn't a U.K. gaming company. The biotech rebranded, lured Bristol Myers Squibb as an investor in its $45 million series A and snagged a Nurix executive to lead ...